Francesca Ligorio

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Francesca Ligorio, Giovanni Fucà, Emma Zattarin et al. · Cancers · 2021 · 102 citations · Full text

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

Federico Nichetti, Francesca Ligorio, Emma Zattarin et al. · Cancers · 2019 · 64 citations · Full text

Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial

Francesca Ligorio, Giovanni Fucà, Leonardo Provenzano et al. · European Journal of Cancer · 2022 · 63 citations

Nutrition, Tumor Biology, Standard Anticancer Therapies +12

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

Carmine Carbone, Geny Piro, Francesca Simionato et al. · Clinical Cancer Research · 2017 · 50 citations

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Francesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli et al. · Cancer Letters · 2021 · 44 citations

Breast Oncology, Oncology, Chemoprevention Strategy +11